Dr. Robert Huizinga co-founded Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) and developed the rare disease global clinical program of voclosporin since its inception through to FDA and EMA approvals. Aurinia is one of only three companies in Canada to receive FDA NCE drug approval, and Huizinga is one of the few to see a drug development from beginning to end. During his tenure, he increased US and Canadian shareholder value from <$10 million to a peak $4.2 Billion over 10 years. He has raised over $500 million USD in the public markets and spearheaded international healthcare partnership/out-licensing deals including China, Korea, USA, Japan and Canada.

Huizinga has led and developed teams of highly qualified research leaders internationally and has taught them how to find the attitude that allows their team to perform at the highest level. He has lectured and led leadership classes internationally and at the local level, including motivational talks for Microsoft and Microsoft Canada.

In addition to his real-world experience leading in a biotechnology company that successfully attained drug approvals globally, Huizinga has a PhD (Organizational Leadership) from Regent University. He has published in leadership journals and is the editor of two texts on leadership.

With 20+ years of experience in the healthcare industry spanning clinical care to drug development, executive leadership and leadership development, his passion is helping to make a positive change in the lives of others. As a servant leader, his vision is “To Build Personal Relationships Within And Between Corporations That Can Translate Into Corporate Relationships Of Value.” The success of any program, whether for-profit or non-profit, is built upon relationships, and his goal is to help your team find the relationship attitudes that transform your business, transform your team and transforms your world.

CEO, Authors, Leadership Healthcare, Health, Business Leadership, Corporate Strategy, Entrepreneurship, Pharmaceutical, Business, Biotechnology,